Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides calories for metabolic processes, restoring blood glucose levels and reducing protein and fat catabolism. Sodium chloride maintains osmolarity and replaces sodium and chloride losses.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Parenteral source of carbohydrates and electrolytes,Treatment of fluid and electrolyte depletion,Maintenance fluid therapy,Correction of hypovolemia
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion. Adult: 500-1000 m L per dose at a rate of 2-6 m L/min, frequency dependent on fluid and electrolyte needs. Maximum 40 m L/kg/day.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Glucose half-life is approximately 1.5-2 hours in normal individuals, prolonged in renal impairment or diabetes. Sodium and chloride have no defined half-life as they are electrolytes; their elimination depends on renal function and hydration status.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the citric acid cycle; insulin-dependent uptake. Sodium chloride is not metabolized; excreted renally.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: >99% of administered glucose is metabolized or excreted; sodium and chloride are excreted renally. In dextrose 5% and sodium chloride 0.2%, glucose undergoes metabolism to CO2 and water; excess is excreted renally. Sodium and chloride are almost entirely excreted renally with >90% reabsorption under normal conditions.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Glucose: negligible (<1%). Sodium and chloride: not protein bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Glucose: approximately 0.2-0.25 L/kg; distributes primarily in extracellular fluid. Sodium: 0.6-0.7 L/kg (total body water); chloride: similar. Clinical meaning: initial distribution reflects ECF volume; changes indicate fluid shifts.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% for all components. Not applicable for oral or other routes as this formulation is for IV use only.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
For GFR 30-50 m L/min: close monitoring of electrolytes; GFR <30 m L/min: use with caution, monitor for hypernatremia and fluid overload, reduce infusion rate by 50%.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific adjustment required for Child-Pugh class A or B; use with caution in class C due to risk of fluid overload.
No dosage adjustment required for hepatic impairment.
Intravenous infusion. 5-10 m L/kg per dose as needed; rate not to exceed 0.5-1 g/kg/hour of dextrose. For neonates, avoid unless specific indication due to high sodium load.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Reduce initial infusion rate to 1-2 m L/min due to decreased renal function and higher risk of fluid overload; monitor serum sodium and osmolality closely.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Solutions containing dextrose may be contraindicated in patients with known allergies to corn or corn products. Intrathecal administration is contraindicated.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus,May cause fluid and solute overload leading to dilution of serum electrolytes, overhydration, congested states, or pulmonary edema,Use with caution in patients with heart failure, renal impairment, or severe dehydration,Not for use in patients with intracranial or intraspinal hemorrhage,Air embolism risk if administered via pressurized IV lines
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia and hyperosmolar coma,Hypersensitivity to corn or corn products,Intrathecal administration,Severe dehydration with hypernatremia,Addison's disease without adequate corticosteroid therapy
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. Monitor fluid and electrolyte balance especially if patient is on a low-sodium diet. Dextrose may affect blood glucose; adjust meal timing or insulin accordingly.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk is reported; however, hyperglycemia or electrolyte imbalances in the mother may affect the fetus. Use standard precautions.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Dextrose and sodium chloride are normal blood constituents; transfer into breast milk is not clinically significant. No M/P ratio available; considered safe during breastfeeding.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Total body water increases in pregnancy, potentially expanding distribution volume; however, dosing is based on clinical status. Monitor for fluid overload and electrolyte disturbances. No specific dose adjustment is required for standard maintenance infusions.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This isotonic solution provides 170 kcal/L from dextrose and is used for maintenance hydration and electrolyte replacement. Monitor serum glucose in diabetics; may cause hyperglycemia. Contains 34 m Eq/L sodium and 34 m Eq/L chloride. Avoid in patients with hypernatremia, fluid overload, or significant renal impairment. Use with caution in pediatric and elderly patients due to risk of hyponatremia.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This solution provides sugar and salt to help maintain body fluids and energy.,Tell your healthcare provider if you have diabetes, heart failure, kidney disease, or are on a low-salt diet.,Report any swelling, shortness of breath, headache, nausea, or changes in urination.,Do not drink this solution; it is given intravenously.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides calories for metabolic processes, restoring blood glucose levels and reducing protein and fat catabolism. Sodium chloride maintains osmolarity and replaces sodium and chloride losses.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion. Adult: 500-1000 m L per dose at a rate of 2-6 m L/min, frequency dependent on fluid and electrolyte needs. Maximum 40 m L/kg/day.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk is reported; however, hyperglycemia or electrolyte imbalances in the mother may affect the fetus. Use s. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.